Daniel Westaby
Overview
Explore the profile of Daniel Westaby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westaby D, Jimenez-Vacas J, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286979
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage...
2.
Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, et al.
J Clin Invest
. 2024 Jun;
134(21).
PMID: 38833311
BACKGROUNDClinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports...
3.
Donners R, Figueiredo I, Westaby D, Koh D, Tunariu N, Carreira S, et al.
Cancer Imaging
. 2023 Dec;
23(1):121.
PMID: 38102655
Background: Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study's objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm to facilitate target lesion...
4.
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al.
Nature
. 2023 Oct;
623(7989):1053-1061.
PMID: 37844613
Inflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and...
5.
Neeb A, Figueiredo I, Gurel B, Nava Rodrigues D, Rekowski J, Riisnaes R, et al.
Lab Invest
. 2023 Aug;
103(11):100245.
PMID: 37652207
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating the clinical...
6.
Grochot R, Carreira S, Miranda S, Figueiredo I, Bertan C, Rekowski J, et al.
Eur Urol Open Sci
. 2023 Jun;
52:72-78.
PMID: 37284046
Background: Germline mutations in the ataxia telangiectasia mutated () gene occur in 0.5-1% of the overall population and are associated with tumour predisposition. The clinical and pathological features of -mutated...
7.
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al.
Eur Urol
. 2023 Mar;
83(6):e168-e169.
PMID: 36964041
No abstract available.
8.
Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al.
Oncogene
. 2023 Feb;
42(12):926-937.
PMID: 36725887
Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need...
9.
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al.
Eur Urol
. 2022 Sep;
83(3):224-238.
PMID: 36114082
Background: B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed in prostate cancers (PCs). Understanding its longitudinal expression at emergence of castration resistance and association with tumour genomics are critical to...
10.
Donners R, Fotiadis N, Figueiredo I, Blackledge M, Westaby D, Guo C, et al.
Eur Radiol
. 2022 Jul;
32(10):6820-6829.
PMID: 35881184
Objectives: Investigate the laboratory, imaging and procedural factors that are associated with a tumour-positive and/or NGS-feasible CT-guided sclerotic bone lesion biopsy result in cancer patients. Methods: In total, 113 CT-guided...